Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Thursday. The firm set a “hold” rating on the stock.

Tonix Pharmaceuticals Stock Down 11.1 %

Tonix Pharmaceuticals stock opened at $0.26 on Thursday. The company has a 50 day moving average of $0.25 and a 200-day moving average of $0.33. The stock has a market capitalization of $47.84 million, a PE ratio of 0.00 and a beta of 2.02. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a twelve month low of $0.12 and a twelve month high of $12.48.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts anticipate that Tonix Pharmaceuticals will post -17.63 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.